RU2167155C2 - Замещенные пиримидинтиоалкильные или алкилэфирные соединения и способ ингибирования обратной транскриптазы вирусов - Google Patents

Замещенные пиримидинтиоалкильные или алкилэфирные соединения и способ ингибирования обратной транскриптазы вирусов Download PDF

Info

Publication number
RU2167155C2
RU2167155C2 RU97120116/04A RU97120116A RU2167155C2 RU 2167155 C2 RU2167155 C2 RU 2167155C2 RU 97120116/04 A RU97120116/04 A RU 97120116/04A RU 97120116 A RU97120116 A RU 97120116A RU 2167155 C2 RU2167155 C2 RU 2167155C2
Authority
RU
Russia
Prior art keywords
dihydro
pyridinyl
furo
chloro
tetrahydro
Prior art date
Application number
RU97120116/04A
Other languages
English (en)
Russian (ru)
Other versions
RU97120116A (ru
Inventor
А. НЬЮДЖЕНТ Ричард (US)
А. НЬЮДЖЕНТ Ричард
Г. ВИШКА Донн (US)
Г. ВИШКА Донн
Дж. КЛИК Гари (US)
Дж. КЛИК Гари
Р. ГРЕЙБЕР Дэвид (US)
Р. ГРЕЙБЕР Дэвид
Томас ШЛЯХТЕР Стивен (US)
Томас Шляхтер Стивен
Дж. МЕРФИ Майкл (US)
Дж. МЕРФИ Майкл
МОРРИС Джоел (US)
Моррис Джоел
С. ТОМАС Ричард (US)
С. ТОМАС Ричард
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of RU97120116A publication Critical patent/RU97120116A/ru
Application granted granted Critical
Publication of RU2167155C2 publication Critical patent/RU2167155C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU97120116/04A 1995-05-08 1996-05-03 Замещенные пиримидинтиоалкильные или алкилэфирные соединения и способ ингибирования обратной транскриптазы вирусов RU2167155C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
US08/436,708 1995-05-08

Publications (2)

Publication Number Publication Date
RU97120116A RU97120116A (ru) 1999-09-20
RU2167155C2 true RU2167155C2 (ru) 2001-05-20

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97120116/04A RU2167155C2 (ru) 1995-05-08 1996-05-03 Замещенные пиримидинтиоалкильные или алкилэфирные соединения и способ ингибирования обратной транскриптазы вирусов

Country Status (26)

Country Link
US (1) US6043248A (enExample)
EP (2) EP1449835A3 (enExample)
JP (1) JPH11507017A (enExample)
KR (1) KR100445498B1 (enExample)
CN (2) CN1152022C (enExample)
AT (1) ATE275550T1 (enExample)
AU (1) AU712404B2 (enExample)
BR (1) BR9608265A (enExample)
CA (1) CA2216099C (enExample)
CZ (1) CZ293135B6 (enExample)
DE (1) DE69633332T2 (enExample)
ES (1) ES2227586T3 (enExample)
GE (1) GEP20002297B (enExample)
HU (1) HUP9801995A3 (enExample)
IL (1) IL118075A0 (enExample)
MX (1) MX9708582A (enExample)
NO (1) NO310287B1 (enExample)
NZ (1) NZ307089A (enExample)
PL (1) PL323240A1 (enExample)
PT (1) PT824524E (enExample)
RU (1) RU2167155C2 (enExample)
SK (1) SK150297A3 (enExample)
TW (1) TW450962B (enExample)
UA (1) UA56992C2 (enExample)
WO (1) WO1996035678A1 (enExample)
ZA (1) ZA963281B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
RU2401261C2 (ru) * 2005-03-04 2010-10-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034167A1 (en) * 1997-09-25 2000-09-13 PHARMACIA & UPJOHN COMPANY Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
US6111111A (en) * 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
WO2011103559A1 (en) 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103140474A (zh) * 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
PH12022550783A1 (en) * 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
CA3167672A1 (en) * 2020-01-20 2021-07-29 Agrematch Ltd. Compositions for crop protection
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
JP2025504415A (ja) * 2022-01-12 2025-02-12 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
EP0124630A1 (de) * 1983-05-05 1984-11-14 LUDWIG HEUMANN & CO GMBH Pyrimidin-Thioalkylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Arzneimittel
EP0276825A1 (en) * 1987-01-30 1988-08-03 Nisshin Flour Milling Co., Ltd. 4 (3H)-Quinazolinone derivatives, processes for their preparation and pharmaceutical compositions
EP0391254A2 (en) * 1989-04-06 1990-10-10 Richter Gedeon Vegyeszeti Gyar Rt. Novel thiouracil derivatives pharmaceutical compositions containing them and process for preparing same
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
WO1995007901A1 (en) * 1993-09-17 1995-03-23 The Upjohn Company Substituted tetronic acids useful for treating hiv and other retroviruses
WO1995013267A1 (en) * 1993-11-12 1995-05-18 The Upjohn Company Pyrimidine-thioalkyl and alkylether compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
MX9203454A (es) * 1989-12-28 1992-08-01 Upjohn Co Compuestos anti sida diaromaticos substituidos.
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
KR100236808B1 (ko) * 1991-07-03 2000-02-01 로렌스 티. 마이젠헬더 에이즈 치료약제로서의 치환된 인돌
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
WO1995029897A1 (en) * 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
PL318298A1 (en) * 1994-07-20 1997-06-09 Byk Gulden Lomberg Chem Fab Thiopyridil compounds for fighting against heliobacter

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
EP0124630A1 (de) * 1983-05-05 1984-11-14 LUDWIG HEUMANN & CO GMBH Pyrimidin-Thioalkylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Arzneimittel
US5025016A (en) * 1983-05-05 1991-06-18 Ludwig Heumann & Co. Gmbh Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these compounds, and method of treatment
EP0276825A1 (en) * 1987-01-30 1988-08-03 Nisshin Flour Milling Co., Ltd. 4 (3H)-Quinazolinone derivatives, processes for their preparation and pharmaceutical compositions
EP0391254A2 (en) * 1989-04-06 1990-10-10 Richter Gedeon Vegyeszeti Gyar Rt. Novel thiouracil derivatives pharmaceutical compositions containing them and process for preparing same
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
WO1995007901A1 (en) * 1993-09-17 1995-03-23 The Upjohn Company Substituted tetronic acids useful for treating hiv and other retroviruses
WO1995013267A1 (en) * 1993-11-12 1995-05-18 The Upjohn Company Pyrimidine-thioalkyl and alkylether compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAIDA M. ET AL. Preparation of quinazolines for neoplasm inhibitor or skin preparation. CHEMICAL ABSTRACTS, Columbus Ohio, US, 1994 v.121, № 9. OTA M. ET AL. Preparation of 2-pyridilmethyltio- or 2-pyridilmethylsulfinyl-substituted cyclic compounds for preventing or treating gastropalh. CHEMICAL ABSTRACTS, Columbus Ohio, US, l988, y.l08, №21. SCHICKANEDER H. ET AL. 2-[(3-Pyridiylmethyl)thio]pyrimidine Derivatives: New Bronchosecretolytic Agents. J.MED.CHEM.Washmgton,1987,v.30, p.547-551. MONTGOMERY J.A. ET AL. Synthesis of Potential Anticancer Agents XIX.2-Substituted N-6-Alkyladenines. J.Am.Chem. Soc. Washington, 1959, v.81, p.3962-3969. JIANG J.B. ET AL. Synthesis of Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones. J. .MED.CHEM. Washington, 1990, v.33, p.1721-1728. SAARI W. ET AL. 2-Pyridinone Derivatives: A new Class OF Nonnucleotide, HIV-specific Reverse Transcriptase Inhibitors. J.MED.CHEM. Washington, 1991, v.34, № 9, p.2922-2925. GOLDMAN V.E. ET AL. Pyridinone Derivatives *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
RU2401261C2 (ru) * 2005-03-04 2010-10-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины

Also Published As

Publication number Publication date
KR19990008400A (ko) 1999-01-25
AU5635396A (en) 1996-11-29
NZ307089A (en) 1999-07-29
NO310287B1 (no) 2001-06-18
BR9608265A (pt) 1999-02-02
KR100445498B1 (ko) 2004-11-16
EP0824524A1 (en) 1998-02-25
PT824524E (pt) 2005-01-31
US6043248A (en) 2000-03-28
ES2227586T3 (es) 2005-04-01
GEP20002297B (en) 2000-11-25
DE69633332T2 (de) 2005-09-22
EP0824524B1 (en) 2004-09-08
HUP9801995A2 (hu) 1999-03-29
TW450962B (en) 2001-08-21
NO975129L (no) 1998-01-07
AU712404B2 (en) 1999-11-04
WO1996035678A1 (en) 1996-11-14
EP1449835A3 (en) 2004-09-15
JPH11507017A (ja) 1999-06-22
IL118075A0 (en) 1996-08-04
UA56992C2 (uk) 2003-06-16
ATE275550T1 (de) 2004-09-15
ZA963281B (en) 1997-10-24
CN1535958A (zh) 2004-10-13
CN1183773A (zh) 1998-06-03
CA2216099A1 (en) 1996-11-14
CZ349197A3 (cs) 1998-04-15
MX9708582A (es) 1998-02-28
NO975129D0 (no) 1997-11-07
HK1009446A1 (en) 1999-09-10
SK150297A3 (en) 1998-10-07
EP1449835A2 (en) 2004-08-25
PL323240A1 (en) 1998-03-16
CN1152022C (zh) 2004-06-02
CA2216099C (en) 2005-09-13
CZ293135B6 (cs) 2004-02-18
HUP9801995A3 (en) 1999-04-28
DE69633332D1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
US6043248A (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase
US6583154B1 (en) Compounds and methods which modulate feeding behavior and related diseases
US10487075B2 (en) Substituted mono- and polyazanaphthalene derivatives and their use
MXPA02008240A (es) Moduladores del receptor de adenosina.
JPH07107051B2 (ja) Ｈｉｖ逆転写酵素の阻害物質
KR20000076124A (ko) 1,5-디히드로-피라졸로[3,4-ｄ]-피리미디논 유도체
KR20000057137A (ko) 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
KR100354309B1 (ko) 피리미딘-티오알킬및알킬에테르화합물
US6124306A (en) Thioalkyl alpha substituted pyrimidine compounds
WO2017108203A1 (en) Novel substituted indoline compounds as phosphodiesterase inhibitors
JP2790065B2 (ja) ベンゼンスルホンアミド誘導体及びその製法
JPH08311043A (ja) スルホンアミド誘導体
TW200305567A (en) Compounds and use thereof for decreasing activity of hormonesensitive lipase
TW200303316A (en) Substituted indolizine-like compounds and methods of use

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050504